Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AYRWFNASDAQ:BDTXNASDAQ:PLRXNASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYRWFAyr Wellness$0.27+32.6%$0.20$0.12▼$3.45$31.59M1.95310,382 shs368,524 shsBDTXBlack Diamond Therapeutics$1.70+6.3%$1.64$1.20▼$7.66$96.35M2.811.48 million shs738,431 shsPLRXPliant Therapeutics$1.59+7.4%$1.64$1.10▼$16.52$97.60M1.461.07 million shs843,298 shsSNTISenti Biosciences$3.32+4.7%$3.50$1.52▼$16.94$86.33M2.32800,820 shs156,097 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYRWFAyr Wellness+32.63%+57.35%+55.82%-43.81%-92.03%BDTXBlack Diamond Therapeutics+6.25%+7.59%+9.68%-32.54%-69.48%PLRXPliant Therapeutics+7.43%+3.25%+17.78%-85.08%-86.55%SNTISenti Biosciences+4.73%-25.06%-1.19%-24.89%-7.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYRWFAyr Wellness2.2916 of 5 stars3.34.00.00.00.00.01.3BDTXBlack Diamond Therapeutics3.526 of 5 stars3.54.00.00.03.32.51.3PLRXPliant Therapeutics4.2031 of 5 stars4.02.00.04.72.21.70.6SNTISenti Biosciences2.8592 of 5 stars3.53.00.00.02.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYRWFAyr Wellness 2.50Moderate Buy$3.001,003.35% UpsideBDTXBlack Diamond Therapeutics 3.00Buy$14.60758.82% UpsidePLRXPliant Therapeutics 2.00Hold$13.31737.26% UpsideSNTISenti Biosciences 3.00Buy$10.00201.20% UpsideCurrent Analyst Ratings BreakdownLatest AYRWF, PLRX, SNTI, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/18/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/7/2025AYRWFAyr WellnessVentum Cap MktsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.003/4/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.503/4/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.003/4/2025PLRXPliant TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/4/2025PLRXPliant TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYRWFAyr Wellness$463.63M0.07$0.04 per share7.43$7.39 per share0.04BDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$2.26 per shareN/APLRXPliant Therapeutics$1.58M61.77N/AN/A$7.91 per share0.20SNTISenti Biosciences$2.56M33.72N/AN/A$15.02 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYRWFAyr Wellness-$272.43M-$3.26N/AN/AN/A-48.17%-25.30%-9.94%N/ABDTXBlack Diamond Therapeutics-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%5/8/2025 (Estimated)PLRXPliant Therapeutics-$161.34M-$3.47N/AN/AN/AN/A-48.91%-41.09%5/5/2025 (Estimated)SNTISenti Biosciences-$71.06M-$12.03N/AN/AN/AN/A-154.84%-77.42%5/8/2025 (Estimated)Latest AYRWF, PLRX, SNTI, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025BDTXBlack Diamond Therapeutics$0.10N/AN/AN/A$23.33 millionN/A5/5/2025Q1 2025PLRXPliant Therapeutics-$0.72N/AN/AN/AN/AN/A3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 million3/6/2025Q4 2024AYRWFAyr Wellness-$0.29-$0.41-$0.12-$1.40$114.10 million$113.96 million3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYRWFAyr WellnessN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYRWFAyr Wellness0.761.590.58BDTXBlack Diamond TherapeuticsN/A5.555.55PLRXPliant Therapeutics0.0910.2610.26SNTISenti BiosciencesN/A1.921.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYRWFAyr Wellness0.91%BDTXBlack Diamond Therapeutics95.47%PLRXPliant Therapeutics97.30%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipAYRWFAyr Wellness8.10%BDTXBlack Diamond Therapeutics8.87%PLRXPliant Therapeutics6.40%SNTISenti Biosciences10.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYRWFAyr Wellness2,380116.19 million106.77 millionNot OptionableBDTXBlack Diamond Therapeutics9056.68 million51.57 millionOptionablePLRXPliant Therapeutics9061.39 million56.96 millionOptionableSNTISenti Biosciences426.00 million4.30 millionNot OptionableAYRWF, PLRX, SNTI, and BDTX HeadlinesRecent News About These CompaniesSENTI-202 Shows Positive Preliminary Data in Acute Myeloid LeukemiaApril 30 at 7:04 PM | curetoday.comShareholders That Lost Money on Senti Biosciences, Inc. (SNTI) Should Contact Levi & Korsinsky About Securities Fraud Investigation - SNTIApril 30 at 3:15 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIApril 30 at 11:00 AM | accessnewswire.comSenti Bio to Present at the Citizens JMP Life Sciences ConferenceApril 30 at 9:00 AM | globenewswire.comSenti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in ...April 29 at 6:30 PM | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIApril 29 at 4:45 PM | globenewswire.comSenti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AMLApril 28 at 7:00 AM | globenewswire.comSenti Bio to hold a conference callApril 28 at 4:24 AM | markets.businessinsider.comSenti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual MeetingApril 26, 2025 | nasdaq.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 5.44%April 25, 2025 | aaii.comSenti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ETApril 24, 2025 | globenewswire.comSenti Biosciences Releases KOL Segment Featuring Dr. Stephen Strickland on Advances in Acute Myeloid Leukemia ResearchApril 21, 2025 | quiverquant.comSenti Bio Participates in a Virtual Investor KOL Connect SegmentApril 21, 2025 | globenewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateApril 19, 2025 | marketbeat.comSenti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | globenewswire.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 8.89%April 11, 2025 | aaii.comSenti Bio appoints James Trager to Scientific Advisory BoardApril 11, 2025 | markets.businessinsider.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Biosciences joins Webull’s Corporate Connect ServiceApril 9, 2025 | uk.investing.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 8.41%April 9, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYRWF, PLRX, SNTI, and BDTX Company DescriptionsAyr Wellness OTCMKTS:AYRWF$0.27 +0.07 (+32.63%) As of 04/30/2025 03:59 PM EasternAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.Black Diamond Therapeutics NASDAQ:BDTX$1.70 +0.10 (+6.25%) As of 04/30/2025 04:00 PM EasternBlack Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Pliant Therapeutics NASDAQ:PLRX$1.59 +0.11 (+7.43%) As of 04/30/2025 04:00 PM EasternPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Senti Biosciences NASDAQ:SNTI$3.32 +0.15 (+4.73%) As of 04/30/2025 04:00 PM EasternSenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
